Synergistic era: practice and reflection on TACE combined with systemic therapy in hepatocellular carcinoma

Abstract

The treatment paradigm for hepatocellular carcinoma (HCC) is evolving from traditional stage-based monotherapy toward a synergistic era characterized by the proactive integration of locoregional and systemic therapies. Transarterial chemoembolization (TACE) plus systemic therapy has shown notable synergistic potential, but it also complicates clinical decision-making and trial interpretation. This review briefly outlines advances in TACE and systemic therapy, summarizes key randomized controlled trials of combination therapy, and analyzes core challenges in treatment timing, TACE implementation, endpoint design, and patient selection. Although combination regimens have not consistently demonstrated significant overall survival (OS) benefits in intermediate-to-advanced HCC, improvements in progression-free survival, objective response rate, and other disease-control endpoints have been increasingly reported. Future prospective trials should look beyond drug selection alone and refine combination timing, clinically meaningful endpoints, TACE standardization, and subgroup selection. These refinements may help determine how early disease-control gains can be translated more consistently into durable OS benefit, particularly for patients with intermediate-stage HCC.

Keywords

Hepatocellular carcinoma / transarterial chemoembolization / immunotherapy / targeted therapy / combination therapy

References

[1] Bray F,Laversanne M,Sung H.et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2024 74 229 63

[2] Liu CJ,Chen PJ. Changing epidemiology of liver disease in Asia: dual infection of HBV and HCV Liver Int 2022 42 1945 54

[3] Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC J Hepatol 2021 75 1476 84

[4] Vogel A,Meyer T,Sapisochin G,Salem R,Saborowski A. Hepatocellular carcinoma Lancet 2022 400 1345 62

[5] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma J Hepatol 2025 82 315 74

[6] Taddei TH,Brown DB,Yarchoan M,Mendiratta-Lala M,Llovet JM. Critical update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma Hepatology 2025 82 272 4

[7] Vogel A,Chan SL,Dawson LA.et al. ; ESMO Guidelines Committee. Electronic address: [e-mail]. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Ann Oncol 2025 36 491 506

[8] Pinato DJ,Murray SM,Forner A.et al. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer. 2021;9:e003311 PMC8487214

[9] Tan J,Fan W,Liu T.et al. TREM2⁺ macrophages suppress CD8⁺ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma J Hepatol 2023 79 126 40

[10] Wang Z,Li Q,Liang B. Hypoxia as a target for combination with transarterial chemoembolization in hepatocellular carcinoma. Pharmaceuticals. 2024;17:1057 PMC11357673

[11] Romero D. Early promising results with addition of an ICI and an anti-angiogenic to TACE Nat Rev Clin Oncol 2025 22 157

[12] Sangro B,Kudo M,Erinjeri JP.et al. ; EMERALD-1 Investigators. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study Lancet 2025 405 216 32 PMC12282661

[13] Kudo M,Ren Z,Guo Y.et al. ; LEAP-012 investigators. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study Lancet 2025 405 203 15

[14] Dong J,Han G,Ogasawara S.et al. LBA2 TALENTACE: a phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC) Ann Oncol 2025 36 S62

[15] Zhu H,Teng G,Fan W.et al. Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable hepatocellular carcinoma eligible for embolization: a multicenter, open-label, randomized, phase 2 study (CAP-ACE) JCO 2025 43 LBA522

[16] Zhou J,Sun H,Wang Z.et al. China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 Edition) Liver Cancer 2025 14 779 835 PMC12503762

[17] Li C, Chen L, Bao H, Wang Y, Zhu G. Synergistic era: Practice and reflection on TACE combined with systemic therapy in hepatocellular carcinoma. SciEriXiv. 2025.

[18] Matsui O,Kobayashi S,Sanada J.et al. Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis Abdom Imaging 2011 36 264 72 PMC3102849

[19] Goldstein HM,Wallace S,Anderson JH,Bree RL,Gianturco C. Transcatheter occlusion of abdominal tumors Radiology 1976 120 539 45

[20] Nakamura H,Hashimoto T,Oi H,Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma Radiology 1989 170 783 6

[21] Llovet JM,Real MI,Montaña X.et al. ; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 2002 359 1734 9

[22] Lo CM,Ngan H,Tso WK.et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 2002 35 1164 71

[23] Zhu HD,Liu R,Jia ZZ.et al. Transarterial chemoembolization for hepatocellular carcinoma: treatment algorithm proposed by Chinese College of Interventionalists(CCI). EngMedicine. 2024;1:1-9

[24] Miyayama S,Matsui O. Superselective conventional transarterial chemoembolization for hepatocellular carcinoma: rationale, technique, and outcome J Vasc Interv Radiol 2016 27 1269 78

[25] de Baere T,Ronot M,Chung JW.et al. Initiative on superselective conventional transarterial chemoembolization results (INSPIRE) Cardiovasc Intervent Radiol 2022 45 1430 40 PMC9499883

[26] Liu B,Gao S,Guo J.et al. Efficacy and safety of hepasphere drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy as the second-line treatment in advanced hepatocellular carcinoma J Hepatocell Carcinoma 2024 11 477 88 PMC10922006

[27] Gjoreski A,Popova-Jovanovska R,Eftimovska-Rogac I,Vejseli J. Safety profile and efficacy of chemoembolization with doxorubicin - loaded polyethylene glycol microspheres in patients with hepatocellular carcinoma Open Access Maced J Med Sci 2019 7 742 6 PMC6447352

[28] Lin CY,Liu YS,Pan KT,Chen CB,Hung CF,Chou CT. The short-term safety and efficacy of TANDEM microspheres of various sizes and doxorubicin loading concentrations for hepatocellular carcinoma treatment Sci Rep 2021 11 12277 PMC8192539

[29] Vogl TJ,Lammer J,Lencioni R.et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial AJR Am J Roentgenol 2011 197 W562 70

[30] Ayyub J,Dabhi KN,Gohil NV.et al. Evaluation of the safety and efficacy of conventional transarterial chemoembolization (cTACE) and drug-eluting bead (DEB)-TACE in the management of unresectable hepatocellular carcinoma: a systematic review Cureus 2023 15 e41943 PMC10351914

[31] Shi D,Ren Y,Liu Y.et al. Temperature-sensitive nanogels combined with polyphosphate and cisplatin for the enhancement of tumor artery embolization by coagulation activation Acta Biomater 2024 185 240 53

[32] Li Q,Shi J,Ruan X.et al. Hypoxia‐ and pH‐responsive metal‐phenolic network‐engineered ferroptosis‐immuno microspheres for transarterial chemoembolization in hepatocellular carcinoma Adv Funct Mater 2025 35 e10798

[33] Wen K,Ren Y,Huang J.et al. Dual-stage drug delivery microspheres amplify tumor starvation through coagulation-enhanced vascular occlusion Small 2025 21 e08070

[34] Zhang M,Zhou J,Jiang X.et al. MoS₂ nanozyme-chlorella hydrogels: pioneering a hepatocellular carcinoma integrative therapy Adv Funct Mater 2025 35 2417125

[35] Xu J,Pei Z,Wang Y.et al. Bioactive microspheres to enhance sonodynamic-embolization-metalloimmune therapy for orthotopic liver cancer Biomaterials 2025 317 123063

[36] Yang N,Sun X,Zhou Y.et al. Liquid metal microspheres with an eddy-thermal effect for magnetic hyperthermia-enhanced cancer embolization-immunotherapy Sci Bull 2023 68 1772 83

[37] Llovet JM,Ricci S,Mazzaferro V.et al. ; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 2008 359 378 90

[38] Kudo M,Finn RS,Qin S.et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Lancet 2018 391 1163 73

[39] Matsui J,Funahashi Y,Uenaka T,Watanabe T,Tsuruoka A,Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase Clin Cancer Res 2008 14 5459 65

[40] Li X,Qiu M,Wang S,Zhu H,Feng B,Zheng L. A phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours Cancer Chemother Pharmacol 2020 85 593 604

[41] Yau T,Park JW,Finn RS.et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial Lancet Oncol 2022 23 77 90

[42] Cheng AL,Qin S,Ikeda M.et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma J Hepatol 2022 76 862 73 PMC9630017

[43] Rimassa L,Chan SL,Sangro B.et al. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC J Hepatol 2025 83 899 908

[44] Yau T,Galle PR,Decaens T.et al. ; CheckMate 9DW investigators. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial Lancet 2025 405 1851 64

[45] Ren Z,Xu J,Bai Y.et al. ; ORIENT-32 study group. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study Lancet Oncol 2021 22 977 90

[46] Qin S,Kudo M,Meyer T.et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial JAMA Oncol 2023 9 1651 9 PMC10557031

[47] Qin S,Gu S,Chan SL.et al. ; CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study Lancet Oncol 2025 26 1598 611

[48] Zhao C,Zhang Y,Wang G.et al. Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial Signal Transduct Target Ther 2025 10 249 PMC12329032

[49] Shi Y,Han G,Zhou J.et al. Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial Lancet Gastroenterol Hepatol 2025 10 658 70

[50] Strebel BM,Dufour JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease Expert Rev Anticancer Ther 2008 8 1743 9

[51] Kudo M,Imanaka K,Chida N.et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma Eur J Cancer 2011 47 2117 27

[52] Lencioni R,Llovet JM,Han G.et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial J Hepatol 2016 64 1090 8

[53] Meyer T,Fox R,Ma YT.et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial Lancet Gastroenterol Hepatol 2017 2 565 75

[54] Kudo M,Ueshima K,Ikeda M.et al. Final results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma Liver Cancer 2022 11 354 67 PMC9294961

[55] Duan X,Li H,Kuang D.et al. Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial Signal Transduct Target Ther 2024 9 304 PMC11557926

[56] Peng Z,Fan W,Zhu B.et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH) J Clin Oncol 2023 41 117 27

[57] Koroki K,Ogasawara S,Ooka Y.et al. Analyses of intermediate-stage hepatocellular carcinoma patients receiving transarterial chemoembolization prior to designing clinical trials Liver Cancer 2020 9 596 612 PMC7548915

[58] Zhu HD,Li HL,Huang MS.et al. ; CHANCE001 Investigators. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001) Signal Transduct Target Ther 2023 8 58 PMC9905571

[59] Jin ZC,Chen JJ,Zhu XL.et al. ; CHANCE2201 Investigators. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study EClinicalMedicine 2024 72 102622 PMC11090892

[60] Liu K, Yang L, Zhang X-M, et al. HIF-1α and VEGF levels for monitoring hepatocellular carcinoma treatment response to transcatheter arterial chemoembolization. Transl Cancer Res. 2017;6:1043-9

[61] Liu K,Min XL,Peng J,Yang K,Yang L,Zhang XM. The changes of HIF-1α and VEGF expression after TACE in patients with hepatocellular carcinoma J Clin Med Res 2016 8 297 302 PMC4780492